Organic compounds -- part of the class 532-570 series – Organic compounds – Carbohydrates or derivatives
Reexamination Certificate
2005-05-31
2005-05-31
Devi, S. (Department: 1645)
Organic compounds -- part of the class 532-570 series
Organic compounds
Carbohydrates or derivatives
C435S320100, C435S326000, C435S327000, C435S328000, C435S329000
Reexamination Certificate
active
06900302
ABSTRACT:
The invention relates to peptide, oligopeptide or polypeptide compounds that are capable of eliciting a protective immune response against the capsular polysaccharide of groupB Streptococcus(GBS), particularly type III GBS. Such compounds are useful in the development of vaccines that are effective against diseases caused by these pathogens.
REFERENCES:
patent: 5476784 (1995-12-01), Rice et al.
patent: 6140091 (2000-10-01), Raso et al.
patent: 6444787 (2002-09-01), Pincus
Ahlers et al., “construction of an HIV-1 peptide vaccine containing a multideterminant helper peptide linked to a V3 loop peptide 18 inducing strong neutralizing antibody responses in mice of multiple MHC haplotypes after two immunizations,”Journal of Immunology150:5647-5665, 1993.
Agadjanyan et al., “peptide mimicry of carbohydrate epitopes on human immunodeficiency virus,”Nature Biotechnology15:547-551, 1997.
Baker et al., “Role of antibody to native type III polysaccharide of group B streptococcus in infant infection,”Pediatrics68(4):544-549, 1981.
Baker et al., “Safety and immunogenicity of group B streptococcal (GBS) polysaccharide (PS) types Ia and Ib-tetanus toxoid (la-TT; Ib-TT) conjugate vaccines in women,”Pediatric Research39:abstract 980, 1996.
Baker et al., “Group B streptococcal infections,” Remington J., Klein J.O., eds.Infectious Diseases of the Fetus and Newborn Infant, 4thed., Chapter 26, 980-1054, 1995.
Baker et al., “Correlation of maternal antibody deficiency with susceptibility to neonatal group B Streptococcal infection,”New England Journal of Medicine294:753-756, 1976.
Bona, “idiotype vaccines: forgotten but not gone,”Nature Medicine4(6):668-669, 1998.
Clarkson et al., “In vitro selection from protein and peptide libraries,”Trends in Biotechnology12:173-184, 1994.
Cull et al., “Screening for receptor ligands using large libraries of peptide linked to the C terminus of the lac repressor,”Proc. Natl. Acad. Sci. USA89:1865-1869, 1992.
Cusumano et al., “Role of gamma interferon in a neonatal mouse model of group B Streptococcal disease,”Infection and Immunity64(8):2941-2944, 1996.
Feldman et al., “The group B streptococcal capsular carbohydrate: immune response and molecular mimiery,” Advances in Experimental Medicine and biology, 435(435):261-269, 1998.
Griffiss et al., “Vaccines against encapsulated bacteria: a global agenda,”Reviews of Infectious Diseases9(1):176-181, 1987.
Hoogenboom, “Designing and optimizing library selection strategies for generating high-affinity antibodies,” Trends in Biotechnology 15:62-70, 1997.
Kasper et al., “Immune response to type III group B streptococcal polysaccharide-tetanus toxoid conjugate vaccine,”J. Clin. Invest.98:2308-2314, 1996.
Kortt et al., “Recombinant anti-sialidase single-chain variable fragment antibody characterization, formation of dimmer and higher-molecular-mass multimers and the solution of the crystal structure of the single-chain variable fragment/sialidase complex,”Eur. J. Biochem.221:151-157, 1994.
Kumar et al., “Universal T Helper cell determinants enhance immunogenicity of a plasmodium falciparum merozoite surface antigen peptide,”Journal of Immunology148:1499-1505, 1992.
Larsson et al., “Experimental vaccination against group B Streptococcus, an encapsulated bacterium, with highly purified preparations of cell surface proteins rib and α,”Infection and Immunity64(9):3518-3523, 1996.
Lett et al., “Immunogenicity of polysaccharides conjugated to peptides containing T- and B-cell epitopes,”Infection and Immunity62(3):785-792, 1994.
Liao et al., “Isolation of a thermostable enzyme variant by cloning and selection in a thermophilc,”Proc. Natl. Acad. Sci. USA83:576-580, 1986thermophile.
Madoff et al., “Protection of neonatal mice from group B streptococcal infection by maternal immunization with Beta C protein,” Infection and Immunity, 60(12):4989-4994, 1992.
Magliani et al., “Therapeutic potential of antiidiotypic single chain antibodies with yeast killer toxin activity,”Nature Biotechnology15:155-158, 1997.
Magliani et al., “Neunatal mouse immunity against group B streotococcal infection by maternal vaccination with recombinant anti-idiotypes,”Nature Medicine4(6):705-709, 1998.
Mancuso et al., “Beneficial effects of interleukin-6 in neonatal mouse models group B streptococcal disease”Infection and Immunity62(11):4997-5002, 1994.
Mancuso et al., “Role of interleukin 12 in experimental neonatal sepsis caused by group B streptococci,”Infection and Immunity65(9):3731-3735, 1997.
Mancuso et al., “Induction of tumor necrosis factor alpha by the group- and type- specific polysaccharides from type III group B Streptococci,”Infection and Immunity62(7):2748-2753, 1994.
Matteakis et al., “An in vitro polysome display system for identifying ligands from very large peptide libraries,”Proc. Natl. Acad. Sci. USA91:9022-9026, 1994.
McNamara et al., “Monoclonal idiotype vaccine against Streptococcus pneumonie infection,”Science226:1325-1326, 1984.
Panina-Bordignon et al., “Universally immunogenic T cell epitopes: promiscuous binding to human MHC class II and promiscuous recognition by T Cells,”Eur. J. Immunol.19:2237-2242, 1989.
Paoletti et al., “Neonatal mouse protection against infection with multiple group B Streptococcal (GBS) serotypes by maternal immunization with a tetravalent GBS polysaccharide-tetanus toxoid conjugate vaccine,”Infection and Immunity62(8):3236-3243, 1994.
Pincus et al., “Peptides that mimic the group B streptococcal type III capsular polysaccharide antigen,”Journal of Immunology, 160(1):293-298, 1998.
Rubens et al., Transposon mutagenesis of type III group B Streptococcus: correlation of capsule expression with virulence.:Proc. Natl. Acad. Sci.USA 84:7208-7212, 1987.
Stein et al., “neonatal administration of idiotype or anti-idiotype primers for protection againstE. coliK13 infection in mice,”J. Exp. Med.160:1001-1041, 1984.
Teti et al., “Synthesis and immunological properties of an O-stearoyl polysaccharide from group B Streptococci,”J. Immunol. Res.4:67-72, 1992.
Von Hunolstein et al., “Soluble antigens from group B Streptococci induce cytokine production in himan blood cultures,”Infection and Immunity65(10):4017-4021, 1997.
Westerink et al., “Development and characterization of an anti-idiotype antibody to the capsular polysaccharide of Neisseria meningitides serogroup C,”Infec. Immun.56:1120-1127, 1988.
Westerink et al., “Anti-idiotypic antibodies to bacterial capsular polysacchardies,”Idiotypic Network and Disease, eds. Cerney & Hiernaux, Chapter 5 107-119, 1990.
Westerink et al., “Peptide mimicry of the meningococcal group C capsular polysaccharide,”Proc. Natl. Acad. Sci. USA92:4021-4025, 1995.
Winter et al., “Making antibodies by phage display technology,”Annu. Rev. Immunol.12:433-455, 1994.
Yelamos et al., “Targeting of non-lg sequences in place of the V segment by somatic hypermutation,”Nature376:225-229, 1995.
Polonelli Luciano
Teti Giuseppe
Chiron S.r.l.
Devi S.
Hale Rebecca M.
LandOfFree
Vaccine formulations comprising antiidiotypic antibodies... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Vaccine formulations comprising antiidiotypic antibodies..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Vaccine formulations comprising antiidiotypic antibodies... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3427356